Imatinib (IM) and Interferon-Alpha (IFN-a) Maintenance Therapy Is Associated with Long-Term DFS in a Subset of Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph plus ALL)

被引：2
|
作者：
Pfeifer, Heike [1 ]
Wystub, Sylvia [2 ]
Binckebanck, A. [1 ]
Wassmann, Barbara
Kaebisch, Andreas
Luebbert, Michael [3 ]
Leimer, Lothar [4 ]
Giagounidis, Aristoteles [5 ]
Gassmann, Winfried [6 ]
Brueck, Patrick [2 ]
Serve, Hubert [1 ]
Hoelzer, Dieter [7 ]
Ottmann, Oliver G. [1 ]
机构：
[1] Goethe Univ Frankfurt, Dept Med, D-60054 Frankfurt, Germany
[2] Goethe Univ Frankfurt, Dept Hematol, D-60054 Frankfurt, Germany
[3] Univ Hosp Freiburg, Dept Hematol & Oncol, Freiburg, Germany
[4] Robert Bosch Krankenhaus, Stuttgart, Germany
[5] St Johannes Hosp, Med Klin 2, Duisburg, Germany
[6] St Marien Krankenhaus gGmbH, Siegen, Germany
[7] Goethe Univ Hosp, Dept Internal Med Hematol & Oncol 2, Frankfurt, Germany
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.1503.1503
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1503
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL)
    Thomas, D. A.
    O'Brien, S. M.
    Faderl, S.
    Kashani, F. Ravandi
    Wierda, W. G.
    Andreeff, M.
    Garris, R. S.
    Champlin, R. E.
    Cortes, J. E.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
    Wassmann, B
    Scheuring, U
    Pfeifer, H
    Binckebanck, A
    Käbisch, A
    Lübbert, M
    Leimer, L
    Gschaidmeier, H
    Hoelzer, D
    Ottmann, OG
    LEUKEMIA, 2003, 17 (10) : 1919 - 1924
  • [23] Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)
    B Wassmann
    U Scheuring
    H Pfeifer
    A Binckebanck
    A Käbisch
    M Lübbert
    L Leimer
    H Gschaidmeier
    D Hoelzer
    O G Ottmann
    Leukemia, 2003, 17 : 1919 - 1924
  • [24] Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)
    B Wassmann
    H Pfeifer
    U Scheuring
    SA Klein
    N Gökbuget
    A Binckebanck
    H Martin
    H Gschaidmeier
    D Hoelzer
    OG Ottmann
    Leukemia, 2002, 16 : 2358 - 2365
  • [25] Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib
    Tiribelli, Mario
    Sperotto, Alessandra
    Candoni, Anna
    Simeone, Erica
    Buttignol, Silvia
    Fanin, Renato
    LEUKEMIA RESEARCH, 2009, 33 (01) : 174 - 177
  • [26] Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
    Lim, Sung-Nam
    Joo, Young-Don
    Lee, Kyoo-Hyung
    Kim, Dae-Young
    Lee, Je-Hwan
    Lee, Jung-Hee
    Chi, Hyun-Sook
    Yun, Sung-Cheol
    Lee, Won Sik
    Lee, Sang Min
    Park, Seonyang
    Kim, Inho
    Sohn, Sang Kyun
    Moon, Joon Ho
    Ryoo, Hun-Mo
    Bae, Sung Hwa
    Hyun, Myung Soo
    Kim, Min Kyoung
    Kim, Hyeoung Joon
    Yang, Deok-Hwan
    Eom, Hyeon-Seok
    Lee, Gyeong-Won
    Jung, Chul Won
    Won, Jong-Ho
    Kim, Hawk
    Lee, Jae-Hoon
    Shin, Ho-Jin
    Jang, Dae-Young
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (11) : 1013 - 1020
  • [27] Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?
    Khadadah, Fatima M.
    Andrews, Claire
    Atenafu, Eshetu G.
    Schuh, Andre C.
    Maze, Dawn
    Yee, Karen
    Jarallah, Osamah Jamal S.
    Minden, Mark D.
    Schimmer, Aaron D.
    Chan, Steven M.
    Gupta, Vikas
    Kim, Dennis Dong Hwan
    Sibai, Hassan
    BLOOD, 2022, 140 : 3169 - 3170
  • [28] LONG-TERM SURVIVAL OUTCOMES OF ADULT PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH IMATINIB OR DASATINIB
    Vahdani, G.
    Jeong, A. -R.
    Ghaznavi, Z.
    Hsiao, W.
    Tulpule, V.
    Akhtari, M.
    HAEMATOLOGICA, 2017, 102 : 665 - 665
  • [29] Nilotinib in patients (pts) with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL) who are resistant or intolerant to imatinib
    Ottmann, Oliver G.
    Larson, Richard A.
    Kantarjian, Hagop M.
    le Coutre, Philipp
    Baccarani, Michele
    Haque, Ariful
    Gallagher, Neil
    Giles, Francis
    BLOOD, 2007, 110 (11) : 828A - 828A
  • [30] LONG-TERM OUTCOME OF RELAPSED ADULT PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH CONTINUOUS IMATINIB PLUS COMBINATION CHEMOTHERAPY
    Lim, S.
    Joo, Y. D.
    Lee, J. H.
    Lee, J. H.
    Kim, D. Y.
    Sohn, B. S.
    Lee, K. H.
    Kim, I. H.
    HAEMATOLOGICA, 2016, 101 : 357 - 357
12345